Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 1997

View Archived Issues

Glaxo obtains license to technology and porphyrin compound for dermatological diseases

D-21266 demonstrates advantages over miltefosine in vivo

Positive preclinical results with CB-1267 in combination with 9-cis-RA for prostate cancer

In vivo efficacy and pharmacokinetic profile of XR-9051

TAS-103 shows antitumor activity against orthotopically implanted human cancers

Serine protease inhibitors described by 3-D

Modified p53 constructs prepared by the Wistar Institute

Antineoplastic/immunostimulating glycan discovered by U. of Illinois researchers

Prodrugs of calcitriol disclosed by Wisconsin Alumni Research Foundation

Selective beta3-agonists from Lilly

ET antagonists described by Ciba-Geigy Japan (Novartis)

ImmuLogic receives funds from NIH to develop cocaine vaccine

Schering-Plough evaluates novel farnesyltransferase inhibitor

RPR selects farnesyltransferase inhibitor for in vivo evaluation

Taiho discovers potent and selective cdc25PTP inhibitors

Parke-Davis develops new c-src TK inhibitors

Glycan-conjugated 5-FU for the treatment of hepatocellular cancer/metastases

Sequana and Boehringer Ingelheim expand alliance for asthma research

Retinoid-like compounds that induce apoptosis in cancer cells

Procter & Gamble and Hoechst Marion Roussel to comarket Actonel

Sonus and Valois collaborate on development of aerosol drug delivery system

Lilly prepares raloxifene analogs that reverse MRP-mediated resistance

Penederm receives approval for butenafine in Canada

Dual 5alpha-reductase type I/II inhibitor from Lilly for prostatic cancer

Alpha-Beta Technology acquires MycoTox and expands antifungal program

BioSpecifics receives grant to develop collagenase injection for Dupuytren's disease

Procept's topical microbicide shown to be contraceptive

Effects of L-692429 in obese and nonobese young men

Osaterone enhances bone formation in ovariectomized rats

Update on HemispheRx Biopharma's Ampligen

Hepatoprotective effects of ET antagonist TAK-044

Ono-4007 restores immune responses in tumor-bearing animals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...